EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report

Kazuma Soya iD, Takeru Fujimoto iD, Yu Osaki, Koji Matsumoto, Yusuke Takei, Yoshio Sugino, Tsutomu Maruta, Hiroshi Iwamura

IJU Case Reports · 2026-09 · 9 (5)

DOI: 10.1002/iju5.70252 ↗

Kurz gefasst

Fallbericht in der Zeitschrift IJU Case Reports, online erschienen am 18.08.2026. Verfasst von Kazuma Soya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology National Hospital Organization Himeji Medical Center Himeji Hyogo Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Squamous cell carcinoma is a rare bladder cancer subtype with poor prognosis in advanced stages. Currently, there is no established systemic therapy, including immune checkpoint inhibitors, for this subtype. Case Presentation A 49‐year‐old man with pure bladder squamous cell carcinoma arising from a diverticulum with pelvic lymph node involvement underwent neoadjuvant gemcitabine plus cisplatin followed by robot‐assisted radical cystectomy. Six months later, pulmonary metastases developed, and platinum rechallenge led to rapid progression with pleural dissemination. Pembrolizumab produced a complete response despite programmed cell death ligand‐1 negativity, microsatellite stability, and low tumor mutational burden. Isolated hilar lymph node progression during treatment was managed with radiotherapy, achieving temporary local control. The patient survived 41 months from diagnosis and 30 months after metastasis.

Conclusion

Despite early and aggressive metastatic recurrence after robot‐assisted radical cystectomy, the patient showed a remarkable and durable response to pembrolizumab.

Schlagwörter

Stichwörter der Autor:innen

bladder cancerpembrolizumabsquamous cell carcinoma

Autor:innen und Institutionen

  • Department of Urology National Hospital Organization Himeji Medical Center Himeji Hyogo Japan.
  • Department of Medical Oncology Hyogo Cancer Center Akashi Hyogo Japan.
  • Department of Diagnostic Pathology National Hospital Organization Himeji Medical Center Himeji Hyogo Japan.
  • Department of Radiology National Hospital Organization Himeji Medical Center Himeji Hyogo Japan.

ORCID-Profile: Kazuma Soya, Takeru Fujimoto

Zitieren

APA

Soya, K., Fujimoto, T., Osaki, Y., Matsumoto, K., Takei, Y., Sugino, Y., Maruta, T., & Iwamura, H. (2026). Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report. IJU Case Reports, 9(5). https://doi.org/10.1002/iju5.70252

Vancouver

Soya K, Fujimoto T, Osaki Y, Matsumoto K, Takei Y, Sugino Y, et al. Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report. IJU Case Reports. 2026;9(5). doi:10.1002/iju5.70252

BibTeX
@article{Soya2026,
  author = {Soya, Kazuma and Fujimoto, Takeru and Osaki, Yu and Matsumoto, Koji and Takei, Yusuke and Sugino, Yoshio and Maruta, Tsutomu and Iwamura, Hiroshi},
  title = {Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report},
  journal = {IJU Case Reports},
  year = {2026},
  volume = {9},
  number = {5},
  doi = {10.1002/iju5.70252}
}
Kostenlos starten →